Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis

Accueil
Publications
Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis

Martine AUDIBERT
Directrice de recherche émérite, CERDI-CNRS
Senior Fellow Ferdi
Maryline BONNET
Epicentre, Paris, France, IRD UMI 233 TransVIHMI—UM–INSERM U1175, Montpellier, France
Gabriella FERLAZZO
Médecins Sans Frontières, Paris, France
Helena HUERGA
Epicentre, Paris, France
Joseph SITIENEI
Division of National Strategic Health Programs, Ministry of Health, Nairobi, Kenya
Médecins Sans Frontières, Nairobi, Kenya
Francis VARAINE
Médecins Sans Frontières, Paris, France
Steve WANJALA
IRD UMI 233 TransVIHMI—UM–INSERM U1175, Montpellier, France
Nadia YAKHELEF
Epicentre, Paris, France

CatégorieArticles publiés
Publié le12 février 2020
ÉditeurPLOS ONE

Tuberculosis (TB) is the leading cause of death among HIV-positive patients. We assessed the cost-effectiveness of including lateral-flow urine lipoarabinomannan (LF-LAM) in TB diagnostic algorithms for severely ill or immunosuppressed HIV-positive patients with symptoms of TB in Kenya.

Lire

Ouvrir sur journals.plos.orglien externe (nouvelle fenêtre)

Citer

Yakhelef N., Audibert M., Ferlazzo G., Sitienei J., Wanjala S., et al. (2020) Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis. PLOS ONE 15(1): e0227138. https://doi.org/10.1371/journal.pone.0227138

Programmes

Capital humain

Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis

Flash Info